Related Experiment Videos
Transient athetosis induced by tiagabine
Mario Tombini1, Loredana Pacifici, Francesco Passarelli
1Dipartimento di Neurologia, Università Campus Bio-Medico, Rome, Italy. m.tombini@unicampus.it
Epilepsia
|May 3, 2006
Summary
This case report details a patient experiencing acute athetoid movements linked to increased tiagabine therapy for epilepsy. The movement disorder may stem from drug interactions or underlying neurological conditions.
Area of Science:
- Neurology
- Pharmacology
- Epileptology
Background:
- Antiepileptic drugs (AEDs) are known to cause movement disorders.
- Drug-resistant epilepsy requires careful medication management.
- Tiagabine (TGB) is an antiepileptic drug with a known side effect profile.
Observation:
- A 32-year-old woman with drug-resistant focal epilepsy and hemiparesis developed acute athetoid movements.
- These movements were transiently associated with an escalated dosage of tiagabine (TGB).
Findings:
- This is the first reported case of acute athetosis linked to tiagabine (TGB).
- The possibility of drug interaction, particularly with phenobarbital (PB) enhancing GABAergic transmission, cannot be excluded.
- The patient's underlying static encephalopathy may have predisposed her to this specific extrapyramidal side effect.
Implications:
- Clinicians should be vigilant for movement disorders, including athetosis, during tiagabine (TGB) therapy, especially in patients with pre-existing neurological conditions.
- Potential drug interactions between tiagabine (TGB) and other AEDs, like phenobarbital (PB), should be considered when managing epilepsy.
- Further research is warranted to elucidate the mechanisms underlying tiagabine-induced movement disorders and the role of patient-specific factors.